AR088383A1 - Formulaciones de etanercept estabilizadas con combinaciones de azucares y polioles - Google Patents

Formulaciones de etanercept estabilizadas con combinaciones de azucares y polioles

Info

Publication number
AR088383A1
AR088383A1 ARP120103889A ARP120103889A AR088383A1 AR 088383 A1 AR088383 A1 AR 088383A1 AR P120103889 A ARP120103889 A AR P120103889A AR P120103889 A ARP120103889 A AR P120103889A AR 088383 A1 AR088383 A1 AR 088383A1
Authority
AR
Argentina
Prior art keywords
polyols
sugars
formulations
combinations
etanercept
Prior art date
Application number
ARP120103889A
Other languages
English (en)
Spanish (es)
Original Assignee
Coherus Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Coherus Biosciences Inc filed Critical Coherus Biosciences Inc
Publication of AR088383A1 publication Critical patent/AR088383A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
ARP120103889A 2011-10-18 2012-10-18 Formulaciones de etanercept estabilizadas con combinaciones de azucares y polioles AR088383A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161548518P 2011-10-18 2011-10-18
US201261669480P 2012-07-09 2012-07-09

Publications (1)

Publication Number Publication Date
AR088383A1 true AR088383A1 (es) 2014-05-28

Family

ID=48136153

Family Applications (6)

Application Number Title Priority Date Filing Date
ARP120103889A AR088383A1 (es) 2011-10-18 2012-10-18 Formulaciones de etanercept estabilizadas con combinaciones de azucares y polioles
ARP120103886A AR088380A1 (es) 2011-10-18 2012-10-18 Formulaciones de etanercept estabilizadas con cloruro de sodio
ARP120103884A AR088460A1 (es) 2011-10-18 2012-10-18 Formulaciones de etanercept estabilizadas con aminoacidos
ARP120103888A AR088382A1 (es) 2011-10-18 2012-10-18 Formulaciones de etanercept estabilizadas con xilitol
ARP120103887A AR088381A1 (es) 2011-10-18 2012-10-18 Formulaciones de etanercept estabilizadas con meglumina
ARP120103885A AR088379A1 (es) 2011-10-18 2012-10-18 Formulaciones de etanercept estabilizadas con iones metalicos

Family Applications After (5)

Application Number Title Priority Date Filing Date
ARP120103886A AR088380A1 (es) 2011-10-18 2012-10-18 Formulaciones de etanercept estabilizadas con cloruro de sodio
ARP120103884A AR088460A1 (es) 2011-10-18 2012-10-18 Formulaciones de etanercept estabilizadas con aminoacidos
ARP120103888A AR088382A1 (es) 2011-10-18 2012-10-18 Formulaciones de etanercept estabilizadas con xilitol
ARP120103887A AR088381A1 (es) 2011-10-18 2012-10-18 Formulaciones de etanercept estabilizadas con meglumina
ARP120103885A AR088379A1 (es) 2011-10-18 2012-10-18 Formulaciones de etanercept estabilizadas con iones metalicos

Country Status (28)

Country Link
US (21) US9393305B2 (forum.php)
EP (6) EP2768531A4 (forum.php)
JP (6) JP6220788B2 (forum.php)
KR (7) KR102163150B1 (forum.php)
CN (6) CN103998060B (forum.php)
AR (6) AR088383A1 (forum.php)
AU (6) AU2012326084B2 (forum.php)
BR (6) BR112014009146A8 (forum.php)
CA (6) CA2851628A1 (forum.php)
CY (1) CY1121843T1 (forum.php)
DK (1) DK2768525T3 (forum.php)
EA (6) EA025267B1 (forum.php)
ES (1) ES2734070T3 (forum.php)
HK (3) HK1200721A1 (forum.php)
HR (1) HRP20191215T1 (forum.php)
HU (1) HUE045624T2 (forum.php)
IL (6) IL231827A0 (forum.php)
IN (3) IN2014CN02592A (forum.php)
LT (1) LT2768525T (forum.php)
MX (7) MX2014004725A (forum.php)
PL (1) PL2768525T3 (forum.php)
PT (1) PT2768525T (forum.php)
RS (1) RS59179B1 (forum.php)
SG (6) SG11201401567YA (forum.php)
SI (1) SI2768525T1 (forum.php)
SM (1) SMT201900422T1 (forum.php)
TW (6) TW201325606A (forum.php)
WO (6) WO2013059410A1 (forum.php)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3673919A1 (en) 2005-06-14 2020-07-01 Amgen Inc. Self-buffering protein formulations
IN2014CN02592A (forum.php) * 2011-10-18 2015-09-04 Coherus Biosciences Inc
US10485869B2 (en) 2011-10-18 2019-11-26 Coherus Biosciences, Inc. Etanercept formulations stabilized with meglumine
EP2869816A4 (en) * 2012-07-09 2016-04-20 Coherus Biosciences Inc ETANERCEPT FORMULATIONS WITH CLEAR REDUCTION OF SUBVISIBLE PARTICLES
SG11201501460RA (en) * 2012-09-11 2015-04-29 Coherus Biosciences Inc Correctly folded etanercept in high purity and excellent yield
RU2663727C2 (ru) * 2013-05-02 2018-08-08 Мабксьенсе С.А. Альтернативные составы для химерных полипептидов tnfr:fc
WO2015056613A1 (ja) * 2013-10-15 2015-04-23 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 安定化されたポリペプチド水性製剤
CN112107538A (zh) * 2013-10-24 2020-12-22 阿斯利康(瑞典)有限公司 稳定的水性抗体配制品
CA2930227C (en) 2013-11-29 2021-09-28 Ares Trading S.A. A liquid formulation of a fusion protein comprising tnfr and fc region
IS3008B (is) 2014-05-14 2018-12-15 Calor ehf Stöðgandi lausnir fyrir prótín og peptíð
US10478498B2 (en) 2014-06-20 2019-11-19 Reform Biologics, Llc Excipient compounds for biopolymer formulations
US11357857B2 (en) 2014-06-20 2022-06-14 Comera Life Sciences, Inc. Excipient compounds for protein processing
US20160074515A1 (en) 2014-06-20 2016-03-17 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations
US20180200325A1 (en) * 2014-11-18 2018-07-19 Shionogi & Co., Ltd. Stabilized peptide composition
CA2970577A1 (en) * 2014-12-22 2016-06-30 Ares Trading S.A. Liquid pharmaceutical composition
US20180256717A1 (en) * 2014-12-23 2018-09-13 Drug Discovery Laboratory As Protein compositions and use thereof
IL253218B (en) * 2014-12-31 2022-08-01 Lg Chemical Ltd A method for preparing a tnfr–fc fusion protein containing a targeted content of unpurified components
CN104694355B (zh) * 2015-03-20 2016-09-28 吉林大学 葛根护肝保健酒及其制备方法
MX389818B (es) * 2015-08-13 2025-03-20 Landsteiner Scient S A De C V Composicion de estabilidad mejorada de etanercept.
JP5938762B1 (ja) * 2015-09-01 2016-06-22 日揮株式会社 マイクロカプセル製剤及びその製造方法
CN105748414A (zh) * 2016-03-02 2016-07-13 张光泉 抗感染米卡芬净冻干组合物及其制备方法
WO2017179683A1 (ja) * 2016-04-15 2017-10-19 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 ミカファンギンの安定化された医薬組成物
US20180110856A1 (en) * 2016-10-21 2018-04-26 Amgen Inc. Pharmaceutical Formulations and Methods of Making the Same
KR20180046888A (ko) * 2016-10-28 2018-05-09 (주)셀트리온 안정한 약제학적 제제
EP4467565A3 (en) 2016-12-21 2025-03-12 Amgen Inc. Anti-tnf alpha antibody formulations
MX2017013995A (es) * 2017-10-31 2019-05-01 Probiomed S A De C V Formulacion farmaceutica estable de una proteina de fusion.
US20220071901A1 (en) * 2017-11-30 2022-03-10 Bio-Thera Solutions, Ltd. A liquid formulation of humanized antibody for treating il-6-mediated diseases
JP7692699B2 (ja) * 2017-12-22 2025-06-16 サムスン バイオエピス カンパニー リミテッド Ｖｅｇｆアンタゴニストを含む液体組成物
CA3042126A1 (en) 2018-05-03 2019-11-03 Michael A. Portman Methods of treating kawasaki disease
CN111228225B (zh) * 2018-11-28 2022-08-26 鲁南制药集团股份有限公司 一种重组人肿瘤坏死因子受体-Fc融合蛋白冻干制剂
GB201911461D0 (en) * 2019-08-09 2019-09-25 Arecor Ltd Novel composition
EP4065166A4 (en) * 2019-11-26 2023-12-20 Comera Life Sciences, Inc. EXCIPIENT COMPOUNDS FOR BIOPOLYMER FORMULATIONS
JP2024507347A (ja) 2021-02-17 2024-02-19 アレコル リミテッド Ｆｃドメインを含む操作されたタンパク質コンストラクトの水性組成物
CN114788809B (zh) * 2022-01-25 2023-04-14 江苏广承药业有限公司 一种氯雷他定液体制剂

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605690A (en) 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
IT1240314B (it) 1989-09-28 1993-12-07 Immunobiology Research Institutes, Inc. Formulazioni acquose stabilizzate di piccoli peptidi.
EP0620739A4 (en) 1992-09-15 1997-01-15 Immunex Corp Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists.
US5580856A (en) 1994-07-15 1996-12-03 Prestrelski; Steven J. Formulation of a reconstituted protein, and method and kit for the production thereof
US5656730A (en) 1995-04-07 1997-08-12 Enzon, Inc. Stabilized monomeric protein compositions
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US7294481B1 (en) 1999-01-05 2007-11-13 Immunex Corporation Method for producing recombinant proteins
US6677326B2 (en) * 1999-03-15 2004-01-13 Arakis, Ltd. Corticosteroid formulation comprising less than 2.5 mg prednisolone for once daily administration
US20010021380A1 (en) 1999-04-19 2001-09-13 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
CA2366785C (en) 1999-04-19 2012-02-07 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
US20040220103A1 (en) * 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
CA2399436A1 (en) 2000-02-10 2001-08-16 Loran Marie Killar Method of treating or inhibiting cellular injury or cell death
PT1314437E (pt) 2000-08-11 2014-08-29 Chugai Pharmaceutical Co Ltd Preparações estabilizadas contendo anticorpo
WO2003102013A2 (en) * 2001-02-23 2003-12-11 Gonzalez-Villasenor Lucia Iren Methods and compositions for production of recombinant peptides
WO2003072060A2 (en) * 2002-02-27 2003-09-04 Immunex Corporation Polypeptide formulation
CN100563712C (zh) * 2003-02-28 2009-12-02 阿雷斯贸易股份有限公司 肿瘤坏死因子结合蛋白的液体制剂
WO2004082715A1 (ja) 2003-03-20 2004-09-30 Eisai Co., Ltd. 炎症性腸疾患治療剤としての併用医薬
CN100509847C (zh) * 2003-08-01 2009-07-08 安美基公司 结晶肿瘤坏死因子受体2多肽
DK1680137T3 (da) 2003-10-14 2013-02-18 Hoffmann La Roche Makrocyklisk carboxylsyre- og acylsulfonamidforbindelse som inhibitor af HCV-replikation
WO2005082377A1 (ja) * 2004-03-01 2005-09-09 Ajinomoto Co., Inc. 抗ヒトTNF-α抗体活性低下抑制剤
US8206981B2 (en) 2004-03-05 2012-06-26 Dsm Ip Assets B.V. Process for cell culturing by continuous perfusion and alternating tangential flow
US20070196364A1 (en) 2004-07-27 2007-08-23 Human Genome Sciences, Inc. Pharmaceutical Formulation and Process
US7597884B2 (en) * 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
US7300773B2 (en) 2004-08-27 2007-11-27 Wyeth Research Ireland Limited Production of TNFR-Ig
EP1885388B1 (en) 2005-05-10 2013-09-11 Biogen Idec MA Inc. Treating and evaluating inflammatory disorders
CN101237890A (zh) * 2005-06-10 2008-08-06 中外制药株式会社 含有葡甲胺的蛋白质制剂的稳定剂及其利用
EP3673919A1 (en) * 2005-06-14 2020-07-01 Amgen Inc. Self-buffering protein formulations
AU2006330593B2 (en) 2005-12-20 2012-07-26 Bristol-Myers Squibb Company Stable protein formulations
EP1962907A2 (en) 2005-12-21 2008-09-03 Wyeth a Corporation of the State of Delaware Protein formulations with reduced viscosity and uses thereof
AU2007212147A1 (en) 2006-02-03 2007-08-16 Medimmune, Llc Protein formulations
EP2024392A2 (en) 2006-03-17 2009-02-18 Biogen Idec MA, Inc. Stabilized polypeptide compositions
WO2007107340A2 (en) 2006-03-21 2007-09-27 Eugen Oetringer Devices for and methods of analyzing a physiological condition of a physiological subject based on a workload related property
MX2008013535A (es) 2006-04-21 2008-10-29 Amgen Inc Agentes amortiguadores para formulaciones biofarmaceuticas.
EP2059589A2 (en) * 2006-08-01 2009-05-20 Illumigen Biosciences Inc. Pharmaceutical manufacturing methods
CL2007002880A1 (es) 2006-10-06 2008-05-09 Amgen Inc Formulacion estable que comprende un tampon de acido acetico, un tampon de acido glutamico o un tampon de acido succinico con un ph de 4,5 a 7, por lo menos un excipiente que comprende un azucar o un poliol, y un anticuerpo anti-receptor del factor d
EP2094247B1 (en) 2006-10-20 2022-06-29 Amgen Inc. Stable polypeptide formulations
US8192951B2 (en) 2006-11-03 2012-06-05 Wyeth Llc Glycolysis-inhibiting substances in cell culture
CA2672902C (en) * 2006-12-21 2012-11-27 Amgen Inc. Formulations
MX2009009240A (es) 2007-03-02 2009-09-08 Wyeth Corp Uso de cobre y glutamato en el cultivo celular para la produccion de polipeptidos.
EP2014760A1 (en) 2007-06-13 2009-01-14 CMC Biopharmaceuticals A/S A method for producing a biopolymer (e.g. polypeptide) in a continuous fermentation process
EA020456B1 (ru) * 2007-06-14 2014-11-28 Байоджен Айдек Ма Инк. Фармацевтическая композиция, содержащая связывающееся с vla-4 антитело, для подкожной или внутримышечной доставки
NZ602498A (en) 2007-11-30 2014-08-29 Abbvie Inc Protein formulations and methods of making same
NZ586828A (en) * 2008-01-15 2012-12-21 Abbott Gmbh & Co Kg Powdered antibody compositions and methods of making same
JP2011514895A (ja) 2008-02-29 2011-05-12 バイオジェン・アイデック・エムエイ・インコーポレイテッド 精製免疫グロブリン融合タンパク質およびその精製方法
WO2011015926A1 (en) 2009-08-03 2011-02-10 Avesthagen Limited A process of fermentation, purification and production of recombinant soluble tumour necrosis factor alfa receptor (tnfr) - human igg fc fusion protein
CA2770690C (en) 2009-08-11 2021-03-09 Genentech, Inc. Production of proteins in glutamine-free cell culture media
WO2011049798A1 (en) 2009-10-20 2011-04-28 Merck Sharp & Dohme Corp. Use of mixed mode chromatography for the capture and purification of basic antibody products
US20130052195A1 (en) * 2009-12-23 2013-02-28 Emergent Product Development Seattle,LLC Compositions Comprising TNF-alpha and IL-6 Antagonists and Methods of Use Thereof
KR101828623B1 (ko) 2010-04-26 2018-02-12 노파르티스 아게 개선된 세포 배양 배지
CN102946858B (zh) * 2010-05-10 2015-09-30 英塔斯制药有限公司 含有免疫球蛋白Fc的多肽的液体制剂
US20130209465A1 (en) 2010-07-30 2013-08-15 Arecor Ltd. Stabilized Aqueous Antibody Compositions
JP2013535981A (ja) 2010-08-20 2013-09-19 ワイス・エルエルシー 成長因子不含適合細胞の細胞培養
EP2611904A2 (en) 2010-08-31 2013-07-10 Friesland Brands B.V. Culture medium for eukaryotic cells
WO2012051147A1 (en) 2010-10-11 2012-04-19 Abbott Laboratories Processes for purification of proteins
RU2614257C2 (ru) 2011-04-20 2017-03-24 Сандоз Аг СТАБИЛЬНЫЕ ЖИДКИЕ ФАРМАЦЕВТИЧЕСКИЕ ПРЕПАРАТЫ СЛИТОГО БЕЛКА TNFR:Fc
UY34105A (es) 2011-06-03 2012-07-31 Lg Life Sciences Ltd Formulación líquida estable de etanercept
EP2726081A4 (en) 2011-06-29 2015-04-15 Insite Vision Inc METHOD FOR TREATING RECURRING MIBOMEDE DISEASE AND REDUCING THE FREQUENCY FROM THEIR RECURRENCE
EP2726090B1 (en) * 2011-07-01 2020-01-01 Biogen MA Inc. Arginine - free tnfr : fc- fusion polypeptide compositions
KR101857380B1 (ko) 2011-07-01 2018-05-11 암젠 인크 포유동물 세포 배양
US9781540B2 (en) * 2011-07-07 2017-10-03 Qualcomm Incorporated Application relevance determination based on social context
WO2013009526A1 (en) 2011-07-08 2013-01-17 Merck Sharp & Dohme Corp. Method for purifying fc-fusion protein
WO2013025079A1 (en) 2011-08-17 2013-02-21 Hanwha Chemical Corporation Method for preparing active form of tnfr-fc fusion protein
IN2014CN02592A (forum.php) * 2011-10-18 2015-09-04 Coherus Biosciences Inc
SG11201501460RA (en) 2012-09-11 2015-04-29 Coherus Biosciences Inc Correctly folded etanercept in high purity and excellent yield

Also Published As

Publication number Publication date
SG11201401563SA (en) 2014-09-26
BR112014009073A2 (pt) 2017-05-09
AU2012326084A1 (en) 2014-04-17
TWI619504B (zh) 2018-04-01
CN104010658A (zh) 2014-08-27
WO2013059406A1 (en) 2013-04-25
EA201490802A1 (ru) 2014-08-29
US9770510B2 (en) 2017-09-26
EP2768535A1 (en) 2014-08-27
CN103998060B (zh) 2016-12-21
US20190290765A1 (en) 2019-09-26
CN103998061A (zh) 2014-08-20
AU2012326080A1 (en) 2014-04-24
MX2019009176A (es) 2019-10-07
JP6199298B2 (ja) 2017-09-20
TW201325609A (zh) 2013-07-01
AU2012326084B2 (en) 2016-12-15
EA201490804A1 (ru) 2014-09-30
IL231829A0 (en) 2014-05-28
MX2014004732A (es) 2015-05-15
CA2851628A1 (en) 2013-04-25
AR088381A1 (es) 2014-05-28
US20130108632A1 (en) 2013-05-02
SG11201401519RA (en) 2014-07-30
US9943601B2 (en) 2018-04-17
EA201490817A1 (ru) 2014-09-30
US11135267B2 (en) 2021-10-05
BR112014009131A2 (pt) 2017-06-13
US10213508B2 (en) 2019-02-26
LT2768525T (lt) 2019-09-25
BR112014009031A2 (pt) 2017-05-09
AR088460A1 (es) 2014-06-11
JP6113176B2 (ja) 2017-04-12
SMT201900422T1 (it) 2019-09-09
KR20140083037A (ko) 2014-07-03
CA2851639A1 (en) 2013-04-25
EA201490801A1 (ru) 2014-09-30
AU2012326171A1 (en) 2014-04-24
IL231828A0 (en) 2014-05-28
EP2768854A4 (en) 2015-03-11
HK1200721A1 (en) 2015-08-14
US20190298837A1 (en) 2019-10-03
MX2014004725A (es) 2015-02-05
US11129876B2 (en) 2021-09-28
JP6220789B2 (ja) 2017-10-25
HK1200722A1 (en) 2015-08-14
MX2014004728A (es) 2015-05-15
BR112014009146A8 (pt) 2017-06-20
BR112014009022A2 (pt) 2017-05-02
US20160199489A1 (en) 2016-07-14
US9302002B2 (en) 2016-04-05
KR20140091706A (ko) 2014-07-22
TW201325607A (zh) 2013-07-01
MX2014004734A (es) 2015-05-15
KR102068462B1 (ko) 2020-01-22
RS59179B1 (sr) 2019-10-31
MX2014004733A (es) 2015-05-15
TWI644681B (zh) 2018-12-21
CN104011073A (zh) 2014-08-27
AU2012326168A1 (en) 2014-04-24
CN104011073B (zh) 2017-08-25
AU2012326082A1 (en) 2014-04-24
EP2768854A1 (en) 2014-08-27
US20130108633A1 (en) 2013-05-02
US20130101640A1 (en) 2013-04-25
MX367054B (es) 2019-08-02
DK2768525T3 (da) 2019-07-22
JP2014530254A (ja) 2014-11-17
CA2851646A1 (en) 2013-04-25
AU2012326080B2 (en) 2017-02-16
US10980884B2 (en) 2021-04-20
AU2012326171B2 (en) 2017-03-09
US20190290767A1 (en) 2019-09-26
CN103998060A (zh) 2014-08-20
US20190314499A1 (en) 2019-10-17
CA2851651A1 (en) 2013-04-25
PL2768525T3 (pl) 2019-10-31
AU2012326082B2 (en) 2016-12-15
US20190314498A1 (en) 2019-10-17
JP2014530256A (ja) 2014-11-17
US20180028668A1 (en) 2018-02-01
WO2013059410A1 (en) 2013-04-25
US20180193463A1 (en) 2018-07-12
EP2768525B1 (en) 2019-06-19
IL231827A0 (en) 2014-05-28
AU2012326170A1 (en) 2014-04-24
HUE045624T2 (hu) 2020-01-28
SI2768525T1 (sl) 2019-10-30
US10772963B2 (en) 2020-09-15
EA025267B1 (ru) 2016-12-30
HK1200720A1 (en) 2015-08-14
CN104010654B (zh) 2017-10-27
KR20140097184A (ko) 2014-08-06
HK1200719A1 (en) 2015-08-14
IN2014CN02591A (forum.php) 2015-06-26
US10980885B2 (en) 2021-04-20
CY1121843T1 (el) 2020-07-31
TWI595883B (zh) 2017-08-21
US10376588B2 (en) 2019-08-13
JP2014530864A (ja) 2014-11-20
SG11201401517VA (en) 2014-09-26
EP2768533A4 (en) 2015-03-11
MX2014004726A (es) 2015-05-15
CA2851642A1 (en) 2013-04-25
US20190290766A1 (en) 2019-09-26
US20190290768A1 (en) 2019-09-26
EP2768531A4 (en) 2015-03-11
JP6104922B2 (ja) 2017-03-29
JP6220788B2 (ja) 2017-10-25
AU2012326170B2 (en) 2016-12-22
BR112014009146A2 (pt) 2017-06-13
AR088382A1 (es) 2014-05-28
EA026410B1 (ru) 2017-04-28
EP2768532A4 (en) 2015-03-11
IL231826A0 (en) 2014-05-28
US20180125982A1 (en) 2018-05-10
US20130101584A1 (en) 2013-04-25
WO2013059407A1 (en) 2013-04-25
EP2768525A1 (en) 2014-08-27
TW201325606A (zh) 2013-07-01
TW201325611A (zh) 2013-07-01
US20200405865A1 (en) 2020-12-31
JP2014530863A (ja) 2014-11-20
US20190184017A1 (en) 2019-06-20
IN2014CN02527A (forum.php) 2015-06-26
US9801942B2 (en) 2017-10-31
EA028520B1 (ru) 2017-11-30
EP2768532A1 (en) 2014-08-27
HK1200718A1 (en) 2015-08-14
KR20140091705A (ko) 2014-07-22
EA201490815A1 (ru) 2014-09-30
AR088380A1 (es) 2014-05-28
US10987405B2 (en) 2021-04-27
US20160317667A1 (en) 2016-11-03
HK1200851A1 (en) 2015-08-14
SG11201401562RA (en) 2014-09-26
BR112014009087A2 (pt) 2017-04-18
EP2768533A1 (en) 2014-08-27
CN104010657A (zh) 2014-08-27
EP2768525A4 (en) 2015-07-15
US20190328875A1 (en) 2019-10-31
WO2013059405A1 (en) 2013-04-25
KR20200008021A (ko) 2020-01-22
CA2851639C (en) 2020-12-29
TW201325608A (zh) 2013-07-01
TW201325610A (zh) 2013-07-01
US10293049B2 (en) 2019-05-21
US9393305B2 (en) 2016-07-19
US20190314500A1 (en) 2019-10-17
JP2014530862A (ja) 2014-11-20
US10888619B2 (en) 2021-01-12
KR102163150B1 (ko) 2020-10-08
PT2768525T (pt) 2019-07-17
EA025663B1 (ru) 2017-01-30
WO2013059412A1 (en) 2013-04-25
BR112014009131A8 (pt) 2017-06-20
HRP20191215T1 (hr) 2019-10-04
IL231825A0 (en) 2014-05-28
KR20140079491A (ko) 2014-06-26
IL231824A0 (en) 2014-05-28
WO2013059408A1 (en) 2013-04-25
IN2014CN02592A (forum.php) 2015-09-04
EA027325B1 (ru) 2017-07-31
AR088379A1 (es) 2014-05-28
US20190216930A1 (en) 2019-07-18
EA201490803A1 (ru) 2014-09-30
ES2734070T3 (es) 2019-12-04
EP2768535A4 (en) 2015-03-11
AU2012326168B2 (en) 2016-12-15
EP2768531A1 (en) 2014-08-27
SG11201401576WA (en) 2014-10-30
JP2014530255A (ja) 2014-11-17
JP6110393B2 (ja) 2017-04-05
KR20140091707A (ko) 2014-07-22
CN104010654A (zh) 2014-08-27
SG11201401567YA (en) 2014-07-30
CA2851635A1 (en) 2013-04-25

Similar Documents

Publication Publication Date Title
AR088383A1 (es) Formulaciones de etanercept estabilizadas con combinaciones de azucares y polioles
ECSP15004752A (es) Formulaciones de etanercept que muestran una marcada reducción de la cantidad de partículas subvisibles
BR112015004984A2 (pt) formulações aquosas estáveis de adalimumab
CO7111300A2 (es) Formulación de anticuerpos
CL2016000882A1 (es) Composiciones de arni contra el componente c5 del complemento y métodos para su uso (divisional de sol. n°2710-15).
CO7151487A2 (es) Formulación de anticuerpos
BR112014004460A2 (pt) material polimérico para um recipiente isolado
DOP2012000064A (es) Formulaciones farmaceuticas muy concentradas
DOP2016000042A (es) Anticuerpos contra el inhibidor del activador de plasminógeno tipo 1 (pai-1) y usos de los mismos
MX392839B (es) Liberacion autorregulada de ingrediente farmaceutico activo.
PH12015501623A1 (en) Glyco-modified atrial natriuretic peptide
CL2012002317A1 (es) Compuestos derivados de tienopirimidinas, inhibitores de quinasas mnk1/mnk2; composicion farmaceutica; y su uso para elt ratamiento o profilaxis de enfermedades metabolicas, tales como diabetes, daño renal, cancer, enfermedades inflamatorias, entre otras.
UY36542A (es) Formulaciones farmacéuticas para anticuerpos anti-tnf-alfa
AR098168A1 (es) Formulación estable de insulina glulisina
AR086956A1 (es) Formulaciones liofilizadas de fgf-18
BR112016022394A2 (pt) Composição farmaceuticamente aceitável, composição na forma de uma solução injetável farmaceuticamente aceitável, uso da composição, e, método para a preparação da composição injetável farmaceuticamente aceitável
UY35848A (es) Tienopirimidinas
DOP2016000007A (es) Pirazolpiridinas sustituidas
MX2015008528A (es) Formulaciones para conservacion de organos y tejidos con estabilidad y vida util aumentadas.
BR112017026666A2 (pt) armazenagem de longo prazo e conservação de plaquetas
MX2017016862A (es) Composicion farmaceutica estable para administracion oral.
CL2016001130A1 (es) Composiciones sólidas de triglicéridos y usos de estas
CO6470844A2 (es) Solución bebible farmacéutica de telmisartan
AR094203A1 (es) Formulacion farmaceutica en n-[5-[2-(3,5-dimetoxifenil)etil]-2h-pirazol-3-il]-4-[(3r,5s)-3,5-dimetilpiperazin-1-il]benzamida
MX2019004894A (es) Administración de agente activo de la mucosa.

Legal Events

Date Code Title Description
FB Suspension of granting procedure